LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio Statement on the publication of the New European Innovation Agenda

07/07/2022
OTHER
July 7, 2022, Brussels - EuropaBio welcomes the publication of the New European Innovation Agenda (EIA) by the European Commission, which contains initiatives that can contribute to the development of the European biotechnology industry and to deep tech innovation in Europe. The EU should continue to pursue relevant initiatives to make full use of its scientific and industrial excellence to create the necessary conditions for the growth of biotechnology and other innovative industries across Europe.

Several new initiatives proposed under the EIA are set to contribute to move Europe in the right direction, whether it is through allowing innovators to experiment more freely through the creation of regulatory sandboxes, by connecting innovation ecosystems through new regional cooperation structures, improving access to finance for European start-ups and scale-ups, or by attracting and retaining talent in the EU.

Going forward, the EU should focus on legislation that continues to improve an innovation-friendly environment in Europe, facilitating a greater scale of investment and significant global market share originating from Europe. This will further contribute towards tomorrow’s cutting-edge technologies being developed and launched in Europe, dovetailing with initiatives such as the EIA to support the twin green and digital transitions and overall EU sustainability ambitions.

A science-based, proportionate, and predictable policy approach would help leverage the full potential of biotechnology, including new genomic techniques, to benefit citizens, the economy, and the environment. Further promotion of education, training, and skills development to foster European industrial competitiveness and innovation in key enabling technologies (such as biotechnology), will also be critical for Europe’s future, and its ability to achieve strategic autonomy.

Biotechnology already plays and will continue to play a significant role in making European societies healthier, more sustainable, and will help the EU deliver for its citizens in the face of the systemic and global challenges we face in the 21st century.

EuropaBio Statement on the publication of the New European Innovation Agenda


Download

Share
Alexandra Simionca
Alexandra Simionca

Related posts

10/06/2025

EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union


Read more
10/06/2025

The EU economic and scientific future starts with the EU Biotech Act


Read more
04/06/2025

EuropaBio response to EC Call for evidence for an evaluation of “Apply AI Strategy – strengthening the AI continent”


Read more

Important links

  • EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union
  • The EU economic and scientific future starts with the EU Biotech Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.